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A B S T R A C TBackground: Ouwens et al. and Jansen have presented methods for
(network) meta-analysis of survival data by using a multidimensional
treatment effect as an alternative to the synthesis of constant hazards
ratios, which allow for a better fit to the data and the expected
survival of competing interventions for cost-effectiveness analysis.
However, results may be sensitive to the assumed underlying survival
function. Objective: To estimate the expected progression-free survi-
val (PFS) for fulvestrant 500 mg versus alternative hormonal therapies
for postmenopausal women with advanced breast cancer who
relapsed previously by means of a network meta-analysis of currently
available randomized controlled trials using alternative underlying
survival functions. Methods: Eleven randomized controlled trials
were included that evaluated fulvestrant 500 mg (n ¼ 3),
fulvestrant 250 mg (n ¼ 5), fulvestrant 250 mg loading dose (n ¼ 3),
anastrozole 1 mg (n ¼ 3), megestrol acetate (n ¼ 4), letrozole 2.5 mg
(n ¼ 3), letrozole 0.5 mg (n ¼ 3), and exemestane (n ¼ 2). PFS percentages
and numbers at risk were derived from Kaplan-Meier curves and
combined by means of Bayesian network meta-analysis on the basis of
the difference in the shape and scale parameters of the Weibull,see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.10.019
mapigroup.com.
ondence to: Jeroen P. Jansen, MAPI Consultancy, 180log-normal, and log-logistic parametric survival functions. Results: The
log-normal distribution provided the best fit, suggesting that the propor-
tional hazard assumption was not valid. Based on the difference in
expected PFS, it was found that fulvestrant 500 mg is more efficacious
than fulvestrant 250 mg, megestrol acetate, and anastrozole (5.73
months; 95% credible interval [CrI] 10.67, 1.67). Expected PFS for
fulvestrant 500 mg ranged from 10.87 (95% CrI 9.21, 13.07) to 17.02 (95%
CrI 13.33, 22.02) months for the Weibull versus log-logistic distribution.
Conclusions: Fulvestrant 500 mg is expected to be more efficacious than
fulvestrant 250 mg, megestrol acetate, and anastrozole 1 mg and at least
as efficacious as exemestane and letrozole 2.5 mg in terms of PFS among
postmenopausal women with advanced breast cancer after failure on
endocrine therapy. The findings were not sensitive to the distribution,
although the expected PFS varied substantially, emphasizing the impor-
tance of performing sensitivity analyses.
Keywords: fulvestrant, metastatic breast cancer, network meta-
analysis, progression-free survival.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health care decision making is commonly informed by rando-
mized controlled trial (RCT) evidence of the interventions of
interest for a particular disease state [1–4]. Decision makers,
however, are often faced with the challenge of assessing compet-
ing interventions in the absence of an RCT comparing all
interventions of interest simultaneously in a head-to-head fash-
ion [5,6]. As an alternative, indirect treatment comparisons are
advocated to provide estimates of the relative treatment effects
[2,7–9]. Even when direct evidence is available for some interven-
tions of interest, combining these with indirect comparisons in
a network meta-analysis (NMA) may yield a more refined and
precise estimate for the relative treatment effects [3,10].
To inform cost-effectiveness decision making, the expected
survival is required for interventions that aim to increasesurvival. In the case of censored follow-up in RCTs, in order not
to underestimate the expected survival, it is necessary to extra-
polate data beyond the trial period. A recent review by Guyot and
Ouwens [11] of reimbursement submissions to the National
Institute for Health and Clinical Excellence identified that most
time-to-event efficacy analyses were synthesized and extrapo-
lated by using constant hazard ratios (reported or pooled). The
proportional hazards assumption that underlies the evidence
synthesis of survival outcomes based on reported hazard ratios
is implausible if hazard functions of competing interventions
cross and will result in biased expected survival estimates.
Ouwens et al. [12] and Jansen [13] have presented methods for
(network) meta-analysis of survival data by using a multidimen-
sional treatment effect as an alternative to the synthesis of
constant hazards ratios. With known parametric survival func-
tions (e.g., Weibull, log-normal, or log-logistic), the survivalSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Canal Street, Suite 503, Boston, MA 02114, USA.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7404functions of the interventions compared in a trial are modeled
and the difference in the parameters of these functions within a
trial are considered the multidimensional treatment effect,
which are synthesized (and indirectly compared) across RCTs.
The advantage of this approach is that models can be fitted much
closer to the data and the expected survival of competing
interventions for cost-effectiveness analysis (CEA) can be esti-
mated more accurately.
Although the NMA models by Ouwens et al. can be considered
a very flexible and promising approach for the evidence synthesis
of survival data, it is important to evaluate the impact of the
assumed survival functions (e.g., Weibull, log-normal, or log-
logistic) on the expected survival estimates. This methodology is
illustrated by means of an NMA of fulvestrant 500 mg (Faslodex)
and alternative endocrine therapies for advanced breast cancer
among postmenopausal women who have progressed on pre-
vious endocrine therapy.
Fulvestrant is an estrogen receptor (ER) antagonist with no
known agonist effects. It has been approved for the treatment of
postmenopausal women with ER-positive (ERþ) metastatic or
locally advanced breast cancer in which disease has recurred
during or within 1 year of completing adjuvant antiestrogen
therapy or progression on an antiestrogen (i.e., patients who have
recurred or progressed after one previous endocrine therapy).
The phase III Comparison of Faslodex in Recurrent Metastatic
Breast Cancer (CONFIRM) trial demonstrated that fulvestrant 500
mg significantly improved progression-free survival (PFS) com-
pared with fulvestrant 250 mg (hazard ratio 0.8; P ¼ 0.006), with a
nonsignificant trend toward better overall survival (OS) [14]. The
efficacy benefit for fulvestrant 500 mg compared with fulvestrant
250 mg was achievedwithout compromising tolerability or quality
of life [14]. This phase III study led to the approval of the 500-mg
dose in the United States and Europe. The efficacy of the
previously approved fulvestrant 250-mg regimen was evaluated
in several phase II and III RCTs (FINDER1 [15], FINDER2 [16], Trial
0020 by Howell et al. [17], and Trial 0021 by Osborne et al. [18]), two
of which compared fulvestrant 250 mg directly with anastrozole
[17,18]. Using fulvestrant 250 mg as the common comparator, it is
possible to perform an indirect comparison that allows for a
comparison of fulvestrant 500 mg with anastrozole. Moreover, by
extending the evidence base to include RCTs evaluating third-
generation aromatase inhibitors, comparisons to anastrozole,
letrozole, and exemestane are feasible by performing an NMA.
The aim of this article was to estimate the expected PFS with
fulvestrant 500 mg and hormonal therapies for the management of
advanced breast cancer in postmenopausal women who relapsed
previously by means of an NMA based on currently available RCT
evidence. In addition, we demonstrate the impact and importance
of the assumed underlying survival function for the NMA.Methods
Identification and Selection of studies
A systematic literature search was performed in January 2010 to
identify published RCTs evaluating the efficacy of second-line
treatment regimens for patients with postmenopausal ERþ
advanced breast cancer (stage III or IV) who relapsed on prior
endocrine therapy. Medline, Medline In-Process, EMBASE, and
Cochrane databases as well as selected cancer-related confer-
ences were searched by using a predefined search strategy with
terms relevant to advanced breast cancer, RCTs, and the inter-
ventions of interest. In addition, study documents for fulvestrant
were made available by AstraZeneca.
Two reviewers independently evaluated each identified study
against the following predetermined criteria.Population
Postmenopausal ERþ advanced breast cancer (stage III or IV) who
relapsed on prior endocrine therapy.
Interventions
Fulvestrant, letrozole, anastrozole, exemestane, and megestrol
acetate.
Comparisons
Placebo or one of the regimens described under interventions.
Comparisons of the same intervention with different background
treatments were excluded.
Outcomes
PFS or time to progression.
Study design
RCTs.
For each identified study that met the selection criteria,
details were extracted on study design, study population char-
acteristics, and interventions. The hazard ratios and associated
95% confidence intervals were extracted for PFS where reported.
For all studies, except where individual patient-level data were
available (CONFIRM study), the reported Kaplan-Meier curves
were digitized (Engauge Digitaliser v4.1) for each treatment arm
by using the progression percentages for the time points where
the numbers at risk were provided [12]. When the numbers at risk
were not provided, a conservative estimate of uncertainty was
derived for these progression percentages by using the median
duration of follow-up and death. The data set was created on the
basis of extracted progression proportions, which were used to
calculate the incident number of progression events for each
interval and patients at risk at the beginning of that interval.
Analysis
A Bayesian NMA was performed by using the methodology
proposed by Ouwens et al. [12]. With this approach, the progres-
sion of patients over time of the interventions compared in a trial
is modeled with parametric survival functions and the difference
in the shape and scale parameters of these functions between
interventions is synthesized and indirectly compared across
trials. The following parametric survival functions were used
and compared: 1) Weibull, 2) log-normal, and 3) log-logistic.
Additional details on these models have been reported previously
by Ouwens et al. [12]. To let the shape and scale of survival
distributions be positive, the log shape and log scale were
modeled in the current analysis.
The first 30,000 iterations from the WinBUGS sampler were
discarded as ‘‘burn-in,’’ and the inferences were based on an
additional 30,000 iterations by using two chains. The convergence
of the chains was confirmed by using the Gelman-Rubin statistic.
To avoid influencing the results of the analysis based on prior
beliefs, noninformative prior distributions were used for the
model parameters to be estimated. All models were analyzed
by using Markov Chain Monte Carlo techniques with WinBUGS
1.4.1. WinBUGS codes are available from authors on request.
The deviance information criterion (DIC) was used to compare
the goodness of fit of different models. DIC provides a measure of
model fit that penalizes model complexity according to
DIC¼DþpD, pD¼DD^ [19]. Here D is the posterior mean residual
deviance [20], pD is the effective number of parameters, and D^
is the deviance evaluated at the posterior mean of the model
parameters. The model with the lowest DIC is the model provid-
ing the ‘‘best’’ fit to the data.
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DIC was comparable for the fixed and random effectsmodel. Hence,
on statistical grounds, there was no reason to reject the fixed effects
model in favor of a more complicated random effects model.
The parameters of the survival distribution are presented as well
as the 2.5 and 97.5 percentiles corresponding to the 95% credibility
interval (CrI), representing the range within which there is 95%
probability that the true effect lies. The expected and relative results
for PFS are presented for the case in which the data were fully
extrapolated (i.e., when all patients had progressed) and at 36
months (based on the duration of the CONFIRM trial) to demon-
strate the impact of extrapolation for each alternative distribution.
In addition, median PFS is presented to facilitate the interpretation
of the results, given the importance of this outcome in the literature.Results
Study and patient characteristics
The study selection process is summarized in Figure 1. The
literature search identified 2335 potentially relevant studies.
The first review excluded 2151 of the citations (92% of the
citations) on the basis of the selection criteria. The main reasons
for exclusion were related to the following factors: study design
(32%), duplicates (24%), patient population (15%), and interven-
tion (12%). The full text review of 184 remaining studies excluded
a total of 175 articles owing to patient population (3%), study
design (2%), comparator (1%), intervention (1%), duplicates (o1%),Fig. 1 – Floinaccessible foreign language study (o1%), and outcomes (i.e.,
did not present sufficient PFS information) [21,22]. Overall, nine
relevant publications relating to eight RCTs were identified from
the search of the databases. Clinical study reports were provided
by AstraZeneca for the FINDER studies (FINDER1 and 2) and the
CONFIRM trial, which relate to the RCTs published by Ohno et al.
[15], Pritchard et al. [16], and Di Leo et al. [14]. Therefore, overall
11 RCTs were included in the analysis [14–18,23–29].
In Figure 2, the network of RCTs is presented. Fulvestrant 500 mg
was compared with fulvestrant 250 mg in three RCTs, and the
remaining comparisons to anastrozole 1 mg, megestrol acetate,
letrozole 2.5 mg, and exemestane were linked through fulvestrant
250 mg or fulvestrant 250 mg loading dose (LD). The analysis
included data for fulvestrant 250 mg LD and letrozole 0.5 mg to
strengthen the network, although these doses were of no interest
and therefore results for these treatments are not presented.
Additional data were also available for anastrozole 10 mg [23,24])
and aminoglutethimide [28], which were not included in the
analyses because these comparisons were of no interest for the
current research question.
Details of trial designs and characteristics of patients included
in the RCTs are provided in Tables 1 and 2. The RCTs included
were multicenter trials with a parallel design and were predomi-
nantly based in Europe and North America, with the exception
of the FINDER1 study, which was performed in Japan. Most
RCTs were double-blind, although the megestrol arm in the
RCT published by Buzdar et al. [23,24] was open-label, as were
the studies by Howell et al. [17] and Gershanovich et al. [28]. In
total, the RCTs included 5808 patients. The duration of medianwchart.
Fig. 2 – Network of randomized controlled trials. ANAS1,
anastrozole 1 mg; EXE, exemestane 1 mg; F250, fulvestrant
250 mg; F250LD, fulvestrant 250 mg loading dose; F500,
fulvestrant 500 mg; LETRO 0.5, letrozole 0.5 mg; LETRO2.5,
letrozole 2.5 mg; MA, megestrol acetate 160 mg OD or 40 mg
QID; OD, once daily; QID, four times daily. Data for F250 LD
and Letro 0.5 were included in the current network meta-
analysis, but results are not presented for these treatments
as they do not reflect approved doses.
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some studies reported a cutoff point for the analysis, which
ranged from about 6 to 48 months.
The enrolled patients were postmenopausal women with
hormone receptor-positive advanced breast cancer between 60
and 68 years of age on average across the treatment arms. Most
RCTs defined ‘‘advanced’’ based on locally advanced or locore-
gionally recurrent or metastatic disease. In terms of the stage of
disease, the studies did not consistently report the number and/
or types of metastases, although most studies reported the
dominant sites that often related to visceral involvement, bone,
or soft tissue metastases. There were some differences in terms
of the proportion of patients with visceral involvement, ranging
from approximately 16% to 64% across the treatment arms,
although the definitions of classifications across studies also
differed. All RCTs required a World Health Organization perfor-
mance score of 2 or lower, except for the studies by Buzdar et al.
[25] and Kaufmann et al. [27], which required a Karnofsky
performance score of at least 50% and an Eastern Cooperative
Oncology Group score of less than or equal to 2, respectively.
Overall, the distribution of patients with a World Health Organi-
zation score of 0 ranged from 47% to 86%. Most RCTs did not
include life-expectancy requirements, although Trial 0020 by
Howell et al. [17], Trial 0021 by Osborne et al. [18], and the
Evaluation of Faslodex and Exemestane Clinical Trial (EFECT)
trial by Chia and Gradishar [26] included only patients with an
estimated life expectancy of at least 3 months whereas the study
by Buzdar et al. [25] required an estimated life expectancy of
6 months. The requirements for the ER status may have
depended on the year of publication owing to changes in treat-
ment practice over time, as there was a range in the proportion of
patients with ERþ status and ER unknown status, ranging from
100% ERþ to less than 50% ERþ across the studies.
In most of the RCTs, patients had received previous treatment
with an antiestrogen, although the three trials evaluating fulves-
trant 500 mg included a mixture of patients who were eitherpost–anti-estrogen or post–aromatase inhibitor whereas the
EFECT study by Chia et al. included only post-aromatase-
inhibitor patients. Most studies excluded patients if they had
received more than one endocrine therapy for advanced disease
[14–18,23,24,27], although this was not clearly specified in all
studies [25,26,28,29] and the RCT by Chia and Gradishar [26]
indicated that about 80% of the patients had received more than
one previous line of endocrine therapy. The proportion of
patients across the treatment arms who had received endocrine
treatment in an adjuvant setting ranged from 33% to 70%.
Network Meta-Analysis
Figure 3 presents the individual study results extracted from the
PFS Kaplan-Meier curves.
In Table 3, estimates for the scale and shape are summarized
for fulvestrant 250 mg, which represents the baseline comparator
used in the analysis. The difference in the scale and shape of the
alternative treatments relative to fulvestrant 250 mg is also given
in the table, as obtained with the fixed effects model. The model
fit statistics for the three distributions suggest that the log-
normal distribution provided the best fit to the data, which was
followed by the log-logistic and Weibull distributions. Given the
difference between the DIC and residual deviance, it can be
argued that the fit of the Weibull model was significantly
improved by the log-normal distribution.
By applying the relative shape and scale for each treatment
to the baseline shape and scale for fulvestrant 250 mg, it is
possible to derive the proportion of patients progression-free over
time, which is presented in Figure 4 for each distribution. The
curves are presented up until 100 months, at which point
effectively all patients had progressed. The amount of extrapola-
tion required for each treatment varied, depending on the data
available per study (Figure 3), with a maximum follow-up of up to
approximately 36 months in the CONFIRM trial. The PFS curves
suggest that fulvestrant 500 mg is generally associated with the
lowest proportion of progressed patients over time across the
distributions. Importantly, the results highlight that PFS curves
for some treatments cross. For example, the early portion of the
exemestane curves is higher than that of the letrozole curve,
which is then reversed in later time points. This result suggests
that the proportional hazard assumption is not valid for the
current data. In addition, the log cumulative hazard figures per
study suggest that the proportional hazards assumption is not
reasonable for all the included RCTs.
Figure 5 compares the alternative distributions for fulvestrant
250 and 500 mg and illustrates that results are similar up until
about 10 to 15 months, after which point the Weibull curves
decrease more steeply compared with the log-normal curves
whereas the log-logistic curves result in the longest ‘‘tail.’’
By evaluating the area under the fully extrapolated curves, the
expected (or average) PFS was evaluated per treatment, which is
presented in Figure 6A. This demonstrates that the results of the
log-logistic distribution consistently yielded the highest expected
values, which was followed by the log-normal and the Weibull
distributions. Although the difference between treatments was
minimal in some cases, the expected PFS per treatment followed
the same pattern across the distributions, with fulvestrant 500 mg
resulting in the longest expected PFS, followed by exemestane,
letrozole 2.5 mg, fulvestrant 250 mg, anastrozole 1 mg, and
megestrol acetate. For each treatment, however, the expected PFS
varied substantially across the distributions. Because fulvestrant 500
mg resulted in the longest expected PFS, the differences across the
distributions in terms of expected PFS were the most pronounced,
varying from 10.87 (95% credible interval [CrI] 9.21, 13.07) to 14.6
(95% CrI 11.44, 19.26) to 17.02 (95% CrI 13.33, 22.02) months for the
Weibull, log-normal, and log-logistic distributions, respectively. This
Table 1 – Key study characteristics for all randomized controlled trials.
Study Treatment N Centers Follow-up
Di Leo et al. [14]:
CONFIRM (phase III)
Faslodex 500 mg 362 128 centers in 17
countries
Maximum FU 48 mo
Faslodex 250 mg 374
Ohno et al. [15]:
FINDER1 (phase II)
Faslodex 250 mg 45
Japan
Data cutoff for this study was to be
when all patients (except
withdrawals) had been followed
up for at least 24 wk
Faslodex 250 mg loading
dose†
51
Faslodex 500 mgz 47
Pritchard et al. [16]:
FINDER2 (phase II)
Faslodex 250 mg 47
35 centers in six
countries
FU every 12 wk regardless of
treatment discontinuation. Data
cutoff when all patients (except
withdrawals) had been followed
up for at least 24 wk
Faslodex 250 mg loading
dose†
51
Faslodex 500 mgz 46
Howell et al. [17]: Trial
0020 (phase III)
Fulvestrant 250 mgy 222 Europe, Australia, and
South Africa
Median FU of 14.4 mo
Anastrozole 1 mg OD 229
Osborne et al. [18]:
Trial 0021 (phase III)
Fulvestrant 250 mgy 206 North America 16.8 mo
Anastrozole 1 mg OD 194
Buzdar et al. [23,24]:
Phase III
Anastrozole 1 mg OD 263 Two trials, one in
North America (49
centers), the other
in Europe, Australia,
and South Africa (73
centers)
Median FU about 6 mo for 1996;
31 mo for 1998Megestrol acetate 40 mg QID 253
Anastrozole 10 mg ODk 248
Buzdar et al. [25]:
Phase III
Letrozole 0.5 mg 202 120 centers in the
United States,
Canada, and Europe
(seven countries)
18 mo of FU from the first visit of the
last patient enrolledLetrozole 2.5 mg 199
Megestrol acetate (40 mg
QID)
201
Chia and Gradishar
[26]: EFECT (phase
III)
Faslodex 250 mg loading
dose†
351 Argentina, Belgium,
Brazil, Canada,
Denmark, France,
Germany, Hungary,
Israel, Russia, South
Africa, Spain,
Sweden, the United
Kingdom, and the
United States
Median FU for 13 mo for those alive.
Withdrawals preprogression
followed for response until
progression and death.
Mean duration 159  131 d
Exemestane 25 mg OD 342
Kaufmann et al. [29]:
Phase III
Exemestane 25 mg OD 366 144 centers in 19
countries (Europe,
South Africa,
Mexico, Brazil, and
Argentina)
Median FU 48.9 wk (E11.25 mo)
Megestrol acetate 40 mg QID 403
Dombernowsky et al.
[27]
Megestrol acetate 160 mg OD 189 91 centers in 10
countries
Patients monitored for response and
safety for up to 33 mo (median
E5.5 mo) and up to 45 mo for
survival (median 18–20 mo)
Letrozole 0.5 mg OD 188
Letrozole 2.5 mg OD 174
Gershanovich et al.
[28]k
Letrozole 0.5 mg 192
86 centers across 11
countries
TTP involved 9-mo FU; OS involved
39 mo after study initiation. Six
monthly updates of OS were
planned until 90% of the patients
died. Survival analyzed 15 mo
after last enrollment. Median
overall FU was 15 mo.
Letrozole 2.5 mg 185
Aminoglutethimide 250 mg
BIDz
178
BID, twice daily; FU, follow-up; OD, once daily; QID, four times daily; TTP, time to progression.
* One injection on days 0 and 28 and every 28 days.
† Five hundred milligrams intramuscularly on day 0, 250 mg on days 14 and 28, and 250 mg every 28 days thereafter.
z Two injections on days 0, 14, and 28 and every 28 days.
y Once monthly intramuscular injection.
z Data from Buzdar et al. [23,24] for anastrozole 10 mg were not included because this was not considered a treatment of interest.
k Data from Gershanovich et al. [28] for aminoglutethimide were excluded.
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Table 2 – Key patient characteristics at baseline for all randomized controlled trials.
Study Treatment Prior endocrine
therapy
Other previous
therapy
WHO PS ER status Age Dominant site
Di Leo et al. [14]:
CONFIRM
Faslodex 500 mg Adjuvant: 231;
Advanced: 173
Chemo: 185 NR ERþ: 362 Mean ¼ 61.0  11.5 Any visceral: 239
Last treatment: AI:
152; AE: 210
Radio: 215 Bone only: 87
Faslodex 250 mg Adjuvant: 249;
Advanced: 182
Chemo: 200 NR ERþ: 374 Mean ¼ 60.8  11.9 Any visceral: 232
Last treatment: AI:
161; AE: 213
Radio: 206 Bone only: 77
Ohno et al. [15]:
FINDER1
Faslodex 250 mg Adjuvant: 33;
Advanced: 12
Radio: 15 0: 39 ERþ: 45 Mean ¼ 62.5  7.4 Visceral: 26
AI: 35; Tamoxifen:
19
Chemo: 25 1: 6 No visceral: 19
Faslodex 250 mg
LD†
Adjuvant: 34;
Advanced: 17
Radio: 12 0: 44 ERþ: 51 Mean ¼ 62.4  9.5 Visceral: 28
AI: 38; Tamoxifen:
19
Chemo: 37 1: 6 No visceral: 23
2: 1
Faslodex 500 mgz Adjuvant: 34;
Advanced: 12
Radio: 21 0: 40 ERþ: 47 Mean ¼ 62.7  9.1 Visceral: 27
AI: 35; Tamoxifen:
23
Chemo: 33 1: 7 No visceral: 20
Pritchard et al. [16]:
FINDER2
Faslodex 250 mg Adjuvant: 31;
Advanced: 16
Radio: 25 0: 26 ERþ: 47 Mean ¼ 63.7  9.9 Visceral: 34
AI: 29; Tamoxifen:
28
Chemo: 28 1: 20 No visceral: 14
Faslodex 250 mg
LD†
Adjuvant: 33;
Advanced: 18
Radio: 29 0: 31 ERþ: 51 Mean ¼ 68.1  9.9 Visceral: 41
Anastrozole: 27;
Tamoxifen: 36
Chemo: 25 1: 16 No visceral: 10
2: 4
Faslodex 500 mgz Adjuvant: 25;
Advanced: 20
Radio: 25 0: 31 ERþ: 46 Mean ¼ 65.5  9.1 Visceral: 37
AI: 33; Tamoxifen:
27
Chemo: 26 1: 14 No visceral: 09
2: 1
Howell et al. [17]:
Trial 0020
Fulvestrant 250
mgy
Adjuvant: 121;
Advanced: 126
Cytotoxic chemo:
94
0: 104 ERþ: 156 Median ¼ 64.0
(range ¼ 35–86)
Visceral: 30
1: 93 ER: 15 Soft tissue: 11
2: 25 ER ?: 51 Bone: 48
Anastrozole 1 mg
OD
Adjuvant: 119;
Advanced: 129
Cytotoxic chemo:
98
0: 104 ERþ: 172 Median ¼ 65.0
(range ¼ 33–89)
Visceral: 41
1: 98 ER: 19 Soft tissue: 8
2: 27 ER ?: 37 Bone: 40
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Osborne et al. [18]:
Trial 0021
Fulvestrant 250
mgy
Adjuvant: 122;
Advanced: 110
Cytotoxic chemo:
129
0: 90 ERþ: 170 Mean ¼ 63.0
(range ¼ 33–89)
Visceral: 39
1: 94 ER: 23 Soft tissue: 12
2: 21 ER ?: 13 Bone: 47
Anastrozole 1 mg
OD
Adjuvant: 116;
Advanced: 97
Cytotoxic chemo:
122
0: 84 ERþ: 156 Mean ¼ 62.0
(range ¼ 36–94)
Visceral: 45
1: 95 ER: 22 Soft tissue: 13
2: 15 ER ?: 16 Bone: 43
Buzdar et al. [23,24]
Anastrozole 1 mg
OD
Adjuvant: 121;
Advanced: 128
Surgery: 346
Cytotoxic chemo:
98 Radio: 153
0: 138 1: 91 2:
34
ERþ: 193 ER: 8
Unknown: 62
Mean ¼ 65.0
(range ¼ 29–97)
Visceral: 124
Soft tissue: 99
Bone: 166
Megestrol acetate
40 mg QID
Adjuvant: 92;
Advanced: 138
Surgery: 230
Cytotoxic chemo:
92 Radio: 146
0: 109 1: 101
2: 34 3: 4
ERþ: 168 ER: 16
Unknown: 66
Mean ¼ 66.0
(range ¼ 41–91)
Soft tissue: 95
Bone: 149 Visceral:
102
Anastrozole 10 mg
OD
Adjuvant: 102;
Advanced: 148
Surgery: 237
Cytotoxic chemo:
89 Radio: 156
0: 116 1: 103
2: 32 3/4: 2
ERþ: 173 ER: 16
Unknown: 64
Mean ¼ 65.0
(range ¼ 39–90)
Visceral: 113
Soft tissue: 92
Bone: 156
Buzdar et al. [25]
Letrozole 0.5 mg Adjuvant: 83;
Advanced: 103
Both: 16; No prior:
83; 1 prior: 116;41
prior: 3
No previous
chemo: 130
Karnofsky:
100%:
66 o100%:
136
ERþ: 168 ER: 3
ER ?: 31
Median ¼ 66.5 Visceral: 101
Soft tissue : 44
Bone: 57
Letrozole 2.5 mg Adjuvant: 70;
Advanced: 112
Both: 17; No prior:
70; 1 prior: 126;41
prior: 3
No previous
chemo: 117
Karnofsky:
100%:
58 o100%:
140
ERþ: 160 ER: 0
ER ?: 39
Median ¼ 65.5 Visceral: 95
Soft tissue: 36
Bone: 68
Megestrol acetate
(40 mg quid)
Adjuvant: 78;
Advanced: 104
Both: 19; No prior:
78; 1 prior: 120;41
prior: 3
No previous
chemo: 115
Karnofsky:
100%:
51 o100%:
140
ERþ: 161 ER: 0
ER ?: 40
Median ¼ 65.9 Visceral: 97
Soft tissue: 51
Bone: 53
Chia and Gradishar
[26]: EFECT
Faslodex 250 mg
LD†
Adjuvant AI: 217;
Advanced AI: 313; 1
prior: 145;41
prior: 206
Adjuvant chemo:
147 Chemo for
advanced: 87
Adjuvant radio: 190
Radio for
advanced: 12
0: 194 1: 133
2: 24
ERþ: 334 ER: 9
ER ?: 8
Median ¼ 63.0
(range ¼ 38–88)
Visceral: 197 No
visceral: 154 Skin/
soft tissue: 71
Bone: 236
Exemestane 25 mg
OD
Adjuvant AI: 199;
Advanced AI: 294; 1
prior: 147;41
prior: 195
Adjuvant chemo:
168 Chemo for
advanced: 74
Adjuvant radio: 171
Radio for
advanced: 142
0: 181 1: 149
2: 12
ERþ: 320 ER: 16
ER ?: 6
Median ¼ 63.0
(range ¼ 32–91)
Visceral: 198 No
visceral: 144 Skin/
soft tissue: 58
Bone: 227
Kaufmann et al.
[29]
Exemestane 25 mg
OD
Adjuvant: 145;
Advanced: 42 PD
after initial
response: 179
Cytotoxic chemo:
162
ECOG Median
¼ 1
ERþ/PgRþ: 246
ER ?: 116 Other: 4
Mean ¼ 65.0
(range ¼ 35–89)
Visceral  other:
207
Soft tissue only: 54
Bone only: 61
Megestrol acetate
40 mg QID
Adjuvant: 152;
Advanced: 41 PD
Cytotoxic chemo:
175
ECOG Median
¼ 1
ERþ/PgRþ: 274
ER ?: 128 Other: 4
Mean ¼ 65.0
(range ¼ 30–91)
Visceral  other:
239
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Table 2 – (continued)
Study Treatment Prior endocrine
therapy
Other previous
therapy
WHO PS ER status Age Dominant site
after initial
response: 210
Soft tissue only: 51
Bone only: 73
Dombernowsky
et al. [27]
Megestrol acetate
160 mg OD
Adjuvant: 61;
Therapeutic 
adjuvant: 128
None: 113
Adjuvant: 41
Therapeutic 
adjuvant: 35
0: 87 1: 85 2:
17
ERþPgRþ: 70
ERþ/PgRþ: 41 Er?
PgR?: 78
Mean ¼ 64.0  9.5 Visceral: 77
Soft tissue: 48
Bone: 60
Letrozole 0.5 mg
OD
Adjuvant: 65;
Therapeutic 
adjuvant: 123
None: 114
Adjuvant: 41
Therapeutic 
adjuvant: 33
0: 94 1: 72 2:
22
ERþPgRþ: 69
ERþ/PgRþ: 35 Er?
PgR?: 64
Mean ¼ 64.6  10.5 Visceral: 70
Soft tissue: 57
Bone: 58
Letrozole 2.5 mg
OD
Adjuvant: 57:
Therapeutic 
adjuvant: 117
None: 120
Adjuvant: 36
Therapeutic 
adjuvant: 18
0: 89 1: 60 2:
25
ERþPgRþ: 57
ERþ/PgRþ: 53 Er?
PgR?: 74
Mean ¼ 63.6  9.1 Visceral: 74
Soft tissue: 44
Bone: 52
Gershanovich et al.
[28]
Letrozole 0.5 mg Adjuvant: 68;
Therapeutic: 124
No chemo: 90
Adjuvant chemo:
63 Therapeutic 
adjuvant: 39
0: 69 1: 109 2:
19
ERþ PgRþ: 71
ERþ/PgRþ: 36
Both ?: 85
Mean ¼ 64.0 Visceral: 85
Soft tissue: 43
Bone: 57
Letrozole 2.5 mg Adjuvant: 68;
Therapeutic: 116
No chemo: 97
Adjuvant chemo:
42 Therapeutic 
adjuvant: 46
0: 79 1: 84 2:
22
ERþ PgRþ: 70
ERþ/PgRþ: 42
Both ?: 73
Mean ¼ 66.0 Visceral: 90
Soft tissue: 39
Bone: 54
Aminoglute-
thimide 250 mg
BID
Adjuvant: 71;
Therapeutic: 107
No chemo: 100
Adjuvant chemo:
39 Therapeutic 
adjuvant: 39
0: 68 1: 92 2:
18
ERþ PgRþ: 59
ERþ/PgRþ: 31
Both ?: 88
Mean ¼ 65.0 Visceral: 71
Soft tissue: 46
Bone: 57
AE, antiestrogen; AI, aromatase inhibitor; BID, twice daily; Chemo, chemotherapy; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; LD, loading dose; OD, once daily; PS,
performance score; QID, four times daily; Radio, radiotherapy; WHO, World Health Organization; ?, unknown ER receptor status.
kReceptor status was reported by the ER and PgR groups in some studies (values were summed per ER group).
* One injection on days 0 and 28 and every 28 days.
† Five hundred milligrams intramuscularly on day 0, 250 mg on days 14 and 28, and 250 mg every 28 days thereafter.
z Two injections on days 0, 14, and 28 and every 28 days.
y Once monthly intramuscular injection.
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FULV 250-Finder1
FULV 250-Finder2
FULV 250-Osborne 2002
FULV 250-Howell
FULV 250 LD-Finder1
FULV 250 LD-Finder2
FULV 250 LD-Chia 2008
FULV 500-CONFIRM
FULV 500-Finder1
FULV 500-Finder2
ANAS 1-Osborne 2002
ANAS 1-Buzdar 1996
ANAS 1-Howell
LETRO 0.5-Buzdar 2001
LETRO 0.5 -Dombernowsky 1998
LETRO 0.5-Gershanovich 1998
LETRO 2.5-Buzdar 2001
LETRO 2.5-Gershanovich 1998
MA-Buzdar 2001
MA-Buzdar 1996
MA-Dombernowsky 1998
MA-Kaufmann 2000
EXE-Chia 2008
EXE-Kaufmann 2000
Fulvestrant 250mg Fulvestrant 500mg
Anastrozole 1mg Letrozole 2.5mg
Megestrol acetate Exemestane
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Fig. 3 – Progression-free survival as observed in individual studies by treatment. ANAS1, anastrozole 1 mg; EXE, exemestane
1 mg; F250, fulvestrant 250 mg; F250LD, fulvestrant 250 mg loading dose; F500, fulvestrant 500 mg; LETRO 0.5, letrozole 0.5
mg; LETRO2.5, letrozole 2.5 mg; MA, megestrol acetate 160 mg OD or 40 mg QID; OD, once daily; QID, four times daily.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7 411means that using a log-normal distribution as opposed to a Weibull
distribution implies an additional 3.73 months in the expected PFS
for fulvestrant 500 mg whereas selecting a log-logistic distribution
implies a difference of 6.15 months as compared with the Weibull
distribution. Thus, although the expected PFS was consistent across
the distributions in terms of the order of treatments, the estimates
using a Weibull distribution increased between 30% and 57% by
using a log-logistic distribution across the treatments.
Figure 7A illustrates the difference in the expected PFS for
each treatment versus fulvestrant 500 mg, which suggests that
fulvestrant 500 mg is expected to be more efficacious than
anastrozole, fulvestrant 250 mg, and megestrol acetate. In com-
parison to exemestane and letrozole 2.5 mg, the point estimates
support a trend favoring fulvestrant 500 mg, although the credible
intervals include zero, suggesting that fulvestrant 500 mg
is expected to be at least as efficacious as these alternatives.
To evaluate the sensitivity of results to extrapolation by using
the alternative distributions, the expected value of PFS was also
assessed at 36 months, the time point until which data wereavailable from the CONFIRM study. The expected PFS at 36
months is illustrated in Figure 6B per treatment, and the differ-
ences in expected PFS at 36 months versus fulvestrant 500 mg are
presented in Figure 7B. Again, the expected PFS results were
consistent across the distributions in terms of the order of
treatments. Nevertheless, the differences for each treatment
across distributions were smaller at 36 months as compared
with the fully extrapolated results. Moreover, the interpretation
of the difference in the expected PFS was consistent with the
fully extrapolated results and therefore fulvestrant 500 mg
remained more efficacious than anastrozole, fulvestrant 250
mg, and megestrol acetate and was comparable to exemestane
and letrozole 2.5 mg, regardless of the distribution used.Discussion
This study assessed the comparative efficacy of fulvestrant 500
mg versus alternative endocrine therapies for advanced breast
Weibull distributionLog normal distributionLog logistic distribution
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Table 3 – NMA results: Log scale and shape parameters for fulvestrant 250 mg and difference in parameters for alternatives vs. fulvestrant 250 mg
Model 1: Weibull Model 2: Log-normal Model 3: Log-logistic
Log(scale) (95% CrI) Log(shape)(95% CrI) Log(scale) (95% CrI) Log(shape)(95% CrI) Log(scale) (95% CrI) Log(shape)(95% CrI)
FULV 250 2.15 (2.05, 2.26) 0.03 (0.08, 0.13) 1.73 (1.62, 1.84) 0.13 (0.24, 0.03) 1.61 (1.71, 1.82) 0.25 (0.36, 0.47)
Difference in log(scale)
vs. F250 (95% CrI)
Difference in log(shape)
vs. F250 (95% CrI)
Difference in log(scale)
vs. F250 (95% CrI)
Difference in log(shape)
vs. F250 (95% CrI)
Difference in log(scale)
vs. F250 (95% CrI)
Difference in log(shape)
vs. F250 (95% CrI)
FULV 500 0.26 (0.12, 0.41) 0.06 (0.19, 0.06) 0.22 (0.08, 0.38) 0.10 (0.21, 0.02) 0.23 (0.08, 0.39) 0.11 (0.23, 0.02)
ANAS 1 0.03 (0.20, 0.14) 0.03 (0.11, 0.19) 0.04 (0.21, 0.16) 0.09 (0.06, 0.23) 0.06 (0.25, 0.12) 0.09 (0.07, 0.24)
LETRO 2.5 0.10 (0.18, 0.37) 0.03 (0.25, 0.21) 0.06 (0.21, 0.37) 0.01 (0.24, 0.20) 0.04 (0.21, 0.33) 0.00 (0.24, 0.25)
EXE 0.14 (0.10, 0.39) 0.07 (0.16, 0.29) 0.16 (0.08, 0.43) 0.03 (0.18, 0.24) 0.17 (0.08, 0.42) 0.04 (0.20, 0.28)
MA 0.06 (0.28, 0.17) 0.07 (0.11, 0.27) 0.05 (0.29, 1.61) 0.11 (0.07, 1.34) 0.06 (0.27, 0.18) 0.12 (0.08, 0.33)
Residual
deviance
(Dbar)
2683.50 2113.10 2191.23
DIC 2719.09 2148.63 2226.84
ANAS 1, anastrozole 1 mg; CrI, credible interval; EXE, exemestane 1 mg; F250, fulvestrant 250 mg; F500, fulvestrant 500 mg; LETRO 2.5, letrozole 2.5 mg; MA, megestrol acetate 160 mg OD or
40 mg QID; OD, once daily; QID, four times daily.
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Fig. 5 – Comparison of progression-free survival for
fulvestrant 250 mg and 500 mg as obtained with alternative
distributions. F250, fulvestrant 250 mg; F500, fulvestrant
500 mg.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7 413cancer among postmenopausal women who had progressed on
previous endocrine therapy. Based on the differences in expected
PFS, results of the NMA indicate that fulvestrant 500 mg was
more efficacious than anastrozole, fulvestrant 250 mg, and
megestrol acetate whereas fulvestrant 500 mg was expected to
have comparable PFS to exemestane and letrozole 2.5 mg.
Importantly, the significance of the expected PFS was not sensi-
tive to the choice of distribution or to the extrapolation of results,
and the order of treatments based on the expected PFS was
consistent across distributions. Results, however, suggest that
the choice of distribution had more impact when the results were
fully extrapolated owing to differences in the tails of the alter-
native distributions and there is uncertainty regarding the most
appropriate parametric distribution, which resulted in an
expected PFS for fulvestrant 500 mg ranging from 10.87 (95% CrI
9.21, 13.07) to 17.02 (95% CrI 13.33, 22.02) months.
The current evidence base provides a good example of a
decision problem in which there are no head-to-head RCTs for
fulvestrant 500 mg versus the endocrine therapies of interest,
and it is possible to synthesize the PFS results across the studies
by means of an NMA using fulvestrant 250 mg as a common
comparator. The standard approach to pool and indirectly com-
pare treatments using constant hazard ratios may not accurately
estimate the expected results or associated uncertainty because
the observed PFS curves of the different treatments crossed
each other in some cases. In contrast, the applied method by
Ouwens et al. provides a more flexible method involving a
multidimensional treatment effect to synthesize and extrapolate
the data across studies [12].
This new method also implies that the choice of distributions for
the analysis is extended beyond those relying on the proportional
hazards assumption, allowing two-parameter distributions, such
as the Weibull, log-normal, or log-logistic, to be tested. These three
distributions were selected given their prevalence in CEAs,
although the method by Ouwens et al. extends the use of
accelerated failure time models in trial-based analyses to the
synthesis of RCTs for multiple treatments. Results from the
analysis suggest that the log-normal distribution provided
the best fit to the observed data, which, by definition, violates theproportional hazard assumption and reinforces the importance of
the alternative NMA approach for time-to-event data. Although the
most common distributions were tested, it should be noted that
this study was not an exhaustive analysis of distributions or
combinations of distributions. For example, ‘‘spline’’ models [30]
or fractional polynomial models [13] were not tested. Similarly, the
generalized gamma or F distributions were not tested [31], which
were identified by Ouwens et al. as possible distributions to extend
their NMA methodology [12]. Moreover, all three models tested
belong to the accelerated failure time family, which assumes that
treatments have a multiplicative effect on PFS that is consistent
over a lifetime. Because the shape parameters were comparable
across the treatments, this assumption seems reasonable,
although in the absence of lifetime data it is not possible to fully
assess. As such, there remains some uncertainty regarding the
most appropriate distributions for the current data set.
Given the importance of a lifetime horizon to capture all
relevant outcomes in a CEA, the results were evaluated in terms
of the expected PFS (or the area under the curve) for each
distribution, which required extrapolation for all RCTs. Results
suggest that expected PFS varied substantially depending on the
distribution and that the differences were largely attributed to
the extrapolated ‘‘tails’’ of the alternative distributions (i.e.,
beyond 36 months). Because the goodness-of-fit statistics
assessed only the fit to the observed data, the appropriateness
of the extrapolation was also assessed on the basis of visual
inspection. The log-normal distribution provided a satisfactory fit
to the trial results, although the fit for all three distributions was
suboptimal for the first 3-month period in the CONFIRM trial,
which may be explained by a lag in the treatment effect or the
frequency of the assessment period for PFS (i.e., every 12 weeks).
Nonetheless, the log-normal distribution optimizes the fit of the
model by using all data and maximizes the information used to
extrapolate the results. In the absence of long-term observational
data to validate the choice of distribution for the current
population, results may imply real differences in terms of CEAs
and decision making, reinforcing the importance of performing a
sensitivity analysis with alternative distributions.
Fixed effects models were used to compare the alternative
parametric survival distributions regarding model fit. Based on the
DIC, there was no reason to reject the fixed effects model in favor of
the random effects model. Nevertheless, we point out that one can
still prefer a random effects model over a fixed effects model for
clinical reasons. Limiting the current analysis to only a fixed effects
approach can therefore be considered a limitation. The intent of
this study, however, was to demonstrate the importance of the
survival function selected for an NMA of survival data, which can
be clearly illustrated by using a fixed effects model.
When comparing the fit of the NMA results with that of the
observed trial results, it is important to consider that the model is
based on the relative treatment effects to preserve randomiza-
tion. Consequently, the expected results per treatment are
adjusted on the basis of differences between comparators. For
example, in the current evidence base, the RCTs by Chia et al. and
Kaufmann et al. compared exemestane with fulvestrant 250 mg
LD and megestrol acetate, respectively. Therefore, the results in
the study by Chia et al. are mediated by fulvestrant 250 LD,
whereas results from Kaufmann et al. were linked to anastrozole
1 mg, fulvestrant 250 mg, and fulvestrant 500 mg. Therefore, the
uncertainty associated with the comparison of fulvestrant 500 mg
with exemestane can be explained by the degrees of separation in
the evidence network, and the shift in the PFS curves up from the
observed studies is due to the preservation of the relative effects
versus fulvestrant 250 mg LD or megestrol acetate. In addition,
results for exemestane in both studies had limited follow-up, and
therefore there is more uncertainty regarding the extrapolation of
these results. As a result, a more direct comparison of fulvestrant
F500=Fulvestrant 500mg; F250=Fulvestrant 250mg; F250LD=Fulvestrant 250mg + loading dose; ANAS1=Anastrozole 1mg; MA= 
Megestrol acetate 160mg OD or 40mg QID; LETRO 0.5=Letrozole 0.5mg; LETRO2.5=Letrozole 2.5mg; EXE=Exemestane 1mg; 
F500=Fulvestrant 500mg; F250=Fulvestrant 250mg; F250LD=Fulvestrant 250mg + loading dose; ANAS1=Anastrozole 1mg; MA= 
Megestrol acetate 160mg OD or 40mg QID; LETRO 0.5=Letrozole 0.5mg; LETRO2.5=Letrozole 2.5mg; EXE=Exemestane 1mg; 
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Fig. 6 – (A) Expected progression-free survival (PFS) per treatment in months with full extrapolation. (B) Expected PFS per
treatment in months up until 36 months. ANAS1, anastrozole 1 mg; EXE, exemestane 1 mg; F250, fulvestrant 250 mg;
F250LD, fulvestrant 250 mg loading dose; F500, fulvestrant 500 mg; LETRO 0.5, letrozole 0.5 mg; LETRO2.5, letrozole 2.5 mg;
MA, megestrol acetate 160 mg OD or 40 mg QID; OD, once daily; QID, four times daily.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7414500 mg with exemestane may be required to reduce uncertainty
and to inform a stronger interpretation.
The internal validity of the analysis relies on the quality of the
included RCTs. Overall, the studies were of high quality, although
some potential limitations were identified in terms of blinding for
the studies by Buzdar et al. [23,24], Howell et al. [17], and Gersha-
novich et al. [28]. It should be noted that most studies were phase
III, although some phase II studies were also included. Because the
external validity of the NMA is determined by the patient popula-
tion included in the different trials, the generalizability of the
results may be limited to North America and Europe.The validity of an NMA relies on the absence of systematic
differences of relative treatment effect modifiers across direct
comparisons in an evidence network. If the network includes a
closed loop, both direct and indirect evidence is available for the
pairwise comparisons forming the closed loop and the incon-
sistency between direct and indirect evidence can be assessed.
In the absence of a closed loop, the assumption of no systematic
differences in treatment effect modifiers across the different
comparisons cannot be tested on the basis of the available
treatment effects. Overall, the patients are considered broadly
comparable, although some differences in potential effect
F500=Fulvestrant 500mg; F250=Fulvestrant 250mg; F250LD=Fulvestrant 250mg + loading dose; ANAS1=Anastrozole 1mg; MA= 
Megestrol acetate 160mg OD or 40mg QID; LETRO 0.5=Letrozole 0.5mg; LETRO2.5=Letrozole 2.5mg; EXE=Exemestane 1mg; 
F500=Fulvestrant 500mg; F250=Fulvestrant 250mg; F250LD=Fulvestrant 250mg + loading dose; ANAS1=Anastrozole 1mg; MA= 
Megestrol acetate 160mg OD or 40mg QID; LETRO 0.5=Letrozole 0.5mg; LETRO2.5=Letrozole 2.5mg; EXE=Exemestane 1mg;  
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Fig. 7 – (A) Difference in progression-free survival (PFS) versus fulvestrant 500 in months with full extrapolation.
(B) Difference in PFS versus fulvestrant 500 in months up until 36 months. ANAS1, anastrozole 1 mg; EXE, exemestane 1 mg;
F250, fulvestrant 250 mg; F250LD, fulvestrant 250 mg loading dose; F500, fulvestrant 500 mg; LETRO 0.5, letrozole 0.5 mg;
LETRO2.5, letrozole 2.5 mg; MA, megestrol acetate 160 mg OD or 40 mg QID; OD, once daily; QID, four times daily.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7 415modifiers across the trials were identified in terms of previous
treatment and ERþ status, which should be evaluated further by
using individual patient data, if possible. Inconsistency (in the
presence of a closed loop) can be evaluated by comparing
(pooled) direct effects with indirect or mixed effects obtained
with an NMA for each pairwise contrast [32]. Unfortunately, for
the models with a multidimensional treatment effect (scale and
shape) used in this article, a method for the systematic evalua-
tion of inconsistency has not yet been developed, but is obviously
of interest. A comparison of results obtained with NMA (i.e.,
consistency) models and inconsistency models (using only direct
effects), however, may not show systematic differences given thelimited number of studies in the network. In the current network,
there are four closed loops. For the closed loop of fulvestrant 250,
fulvestrant 500, and fulvestrant 250 LD, there are two 3-arm
studies (the FINDER studies) and one 2-arm study (CONFIRM).
Obviously, the three-arm trials cannot be a source of inconsis-
tency. There would be inconsistency only if the two-arm trial
shows different treatment effects than the three-arm trial.
Similarly, the loop consisting of megestrol acetate, letrozole 2.5 mg,
and letrozole 0.5 mg is also based on two 3-arm trials and one 2-arm
trial. Any violation of the assumption of consistency between direct
and indirect evidence is most likely to occur for trials creating the
larger loop consisting of fulvestrant 250, anastrozole 1 mg, megestrol
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 0 3 – 4 1 7416acetate, exemestane 1 mg, and fulvestrant 250LD. Given the size of
the loop, however, the indirect estimates for any pairwise contrast
will be associated with great uncertainty, and direct evidence will
drive the results of the NMA.
For the current analysis, survival proportions were extracted
from the reported Kaplan-Meier curves, which were used to
calculate the incident number of death and patients at risk per
interval as described by Ouwens et al. [12] assuming censoring
occurs before the events. Recently, Guyot et al. [33] developed an
algorithm to reconstruct data from published Kaplan-Meier
curves with greater accuracy. The application of this more
advanced algorithm is of interest for future NMA of published
survival curves.
Both PFS and OS were analyzed, although the current study
focused on PFS given the interest in applying the method by
Ouwens et al. [12]. In the case of OS, there was no evidence to
suggest that the proportional hazards assumption was invalid
and therefore the results will be presented in a separate publica-
tion. In comparison to OS, PFS is not susceptible to confounding
by differences in subsequent treatments across the studies,
although there is a risk of assessment bias with PFS. Therefore,
OS, as well as the safety and adverse events of these agents,
should be considered in addition to the results of the current
analysis. Finally, the convenience and administration of the
alternative therapies may also play a role in decision making.Conclusion
Fulvestrant has a different mechanism of action to aromatase
inhibitors and has shown efficacy in a phase III setting among
patients who have progressed during endocrine therapy. Based
on the NMA of currently available RCTs, it is expected that
fulvestrant 500 mg is more efficacious than fulvestrant 250 mg,
megestrol acetate, and anastrozole 1 mg and it is at least as
efficacious as exemestane and letrozole 2.5 mg. Because the
differences between treatments in the expected PFS were not
sensitive to the choice of distribution or to the extrapolation of
results, this analysis supports the phase III registration study,
suggesting that fulvestrant 500 mg provides an important
alternative for postmenopausal women with hormone receptor-
positive advanced breast cancer after failure on endocrine
therapy. On the basis of the results of this case study, the new
methodology provides an important alternative if the propor-
tional hazard assumption is not valid, although it is necessary to
test alternative distributions because the expected PFS per treat-
ment may vary significantly, particularly when results are fully
extrapolated owing to the alternative tails of the distributions.Acknowledgments
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